AF
CNTX icon

Advisornet Financial’s Context Therapeutics CNTX Stock Holding History

Advisornet Financial’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$392 – 2019
2024
Q3 		$392 Buy
+200
New +$444 ﹤0.01% 2048

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Advisornet Financial's CNTX Position: Q4 2024 in Review

Advisornet Financial sold out of Context Therapeutics (CNTX) in Q4 2024, closing a stake of 200 shares — an estimated $392 sold.

Advisornet Financial first reported a position in CNTX in Q3 2024 and held it in 1 quarter. The position peaked at $392 in Q3 2024. 52 funds tracked by Wall St. Rank hold CNTX as of Q4 2024.

  • Advisornet Financial reported no remaining Context Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Advisornet Financial sold 200 Context Therapeutics shares in Q4 2024, an estimated $392.
  • Advisornet Financial first reported a position in Context Therapeutics in Q3 2024 and held it in 1 quarter.
  • Advisornet Financial's Context Therapeutics position peaked at $392 in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2024.

Based on Advisornet Financial's 13F filing for Q4 2024, filed 13 Jan 2025.